Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
IPO Year:
Exchange: NYSE
Website: jnj.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/23/2024 | $160.00 → $150.00 | Outperform → Neutral | Daiwa Securities |
5/30/2024 | $160.00 | Neutral | Goldman |
4/18/2024 | $170.00 | Hold → Buy | HSBC Securities |
12/13/2023 | $170.00 → $163.00 | Overweight → Equal Weight | Wells Fargo |
12/1/2023 | $167.00 → $180.00 | Neutral → Buy | UBS |
10/5/2023 | $178.00 | Outperform | RBC Capital Mkts |
9/6/2023 | $175.00 | Hold | HSBC Securities |
5/30/2023 | $185.00 | Buy | Citigroup |
3/29/2023 | $164.00 | Neutral | UBS |
3/1/2023 | $161.00 | Neutral | Guggenheim |
TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today interim data from the ongoing Phase 2 SunRISe-4 study showing neoadjuvant treatment with investigational TAR-200 plus cetrelimab (CET) achieved nearly double the pathological complete response (pCR) rate compared to CET alone in patients with muscle-invasive bladder cancer (MIBC) who are ineligible or refuse neoadjuvant platinum-based chemotherapy and scheduled for radical cystectomy (RC).1 These data were featured as a late-breaking
Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT® beyond lung cancer BARCELONA, Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT® (amivantamab-vmjw) combined with chemotherapy (mFOLFOX6 [FOLFOX] or FOLFIRI) demonstrated promising rapid and durable antitumor activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who have not previously received anti-epidermal growth factor receptor (EGFR) therapy. These data were presented in a mini-oral presentation at the Eu
Post-progression outcomes showed significant and sustained improvement for RYBREVANT® plus standard of care versus chemotherapy alone BARCELONA, Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 3 MARIPOSA-2 study which showed RYBREVANT® (amivantamab-vmjw) combined with chemotherapy led to consistent benefit across post-progression outcomes in adult patients with previously treated non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. The data also reveal a favorable trend toward improved overall survival (OS) compared to chemotherapy alone. Results
The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program1,2,3,4,5 TREMFYA® is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis HORSHAM, Pa., Sept. 11, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic disease of the large intestine in which the lining of the colon becomes inflamed. TREMF
Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT®, a three-fold reduction from 67.4 percent historically seen with standard IRR management SAN DIEGO, Sept. 10, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions (IRRs) with intravenous (IV) RYBREVANT® (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. The study, which included 40 pati
Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 15th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of th
Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies Filing based on the Phase 3 Vivacity-MG3 program, the first-and-only study results in the class demonstrating sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ SPRING HOUSE, Pa., Aug. 29, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking the first approval of nipocalimab globally for the treatment of people living with generalized myasthe
Four RYBREVANT® (amivantamab-vmjw) studies feature compelling new findings in lung and colorectal cancers New TAR-200 data reveal the potential of organ-sparing therapy for the treatment of bladder cancer RARITAN, N.J., Aug. 27, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that 11 oral presentations from the Company's industry-leading solid tumor portfolio and pipeline will be featured at the 2024 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) 2024 Congress. Twenty-seven studies (23 company-sponsored and four investigator-initiated), including four late-breaking abstracts, will feature new data in lung, bladder, prostate, and
Johnson & Johnson (NYSE:JNJ) today announced that Dr. Peter M. Fasolo will retire from his position as Executive Vice President, Chief Human Resources Officer at the end of this year, following 16 years of leadership and service to the Company. Throughout his distinguished career, Dr. Fasolo has worked with the organization's Board of Directors and partnered with three company CEOs to shape and grow the Company's human capital strategy. He will be succeeded in this role by Kristen Mulholland, a strong Credo-based leader who has had an exceptional career with depth and breadth across the Company's Innovative Medicine and MedTech sectors, managed business unit HR for the Company's global co
V-Wave's Novel and Minimally Invasive Interatrial Shunt is Designed to Treat Heart Failure and Addresses Significant Treatment Gap Device Further Strengthens Johnson & Johnson MedTech's Position in Cardiovascular Johnson & Johnson1 (NYSE:JNJ) today announced that it has entered into a definitive agreement to acquire V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. Under the terms of the agreement, Johnson & Johnson will acquire V-Wave for an upfront payment of $600 million, subject to customary adjustments, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billi
8-K - JOHNSON & JOHNSON (0000200406) (Filer)
N-PX - JOHNSON & JOHNSON (0000200406) (Filer)
8-K - JOHNSON & JOHNSON (0000200406) (Filer)
13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)
10-Q - JOHNSON & JOHNSON (0000200406) (Filer)
8-K - JOHNSON & JOHNSON (0000200406) (Filer)
11-K/A - JOHNSON & JOHNSON (0000200406) (Filer)
11-K - JOHNSON & JOHNSON (0000200406) (Filer)
11-K - JOHNSON & JOHNSON (0000200406) (Filer)
SD - JOHNSON & JOHNSON (0000200406) (Filer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)
SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)
SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)
SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)
SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)
SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)
SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)
SC 13G - JOHNSON & JOHNSON (0000200406) (Subject)
SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)
Daiwa Securities downgraded Johnson & Johnson from Outperform to Neutral and set a new price target of $150.00 from $160.00 previously
Goldman resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $160.00
HSBC Securities upgraded Johnson & Johnson from Hold to Buy and set a new price target of $170.00
Wells Fargo downgraded Johnson & Johnson from Overweight to Equal Weight and set a new price target of $163.00 from $170.00 previously
UBS upgraded Johnson & Johnson from Neutral to Buy and set a new price target of $180.00 from $167.00 previously
RBC Capital Mkts initiated coverage of Johnson & Johnson with a rating of Outperform and set a new price target of $178.00
HSBC Securities initiated coverage of Johnson & Johnson with a rating of Hold and set a new price target of $175.00
Citigroup resumed coverage of Johnson & Johnson with a rating of Buy and set a new price target of $185.00
UBS initiated coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $164.00
Guggenheim initiated coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $161.00
Johnson & Johnson's (NYSE:JNJ) short percent of float has fallen 14.77% since its last report. The company recently reported that it has 17.99 million shares sold short, which is 0.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.31 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short int
Guggenheim Partners initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. The investment thesis centers around a positive view of its lead asset ESK-001, a next-gen TYK2 inhibitor currently in development for plaque psoriasis and systemic lupus erythematosus (SLE). The company’s management expects to initiate a Phase 3 trial for plaque psoriasis in the second half of 2024, and data from the SLE study are expected in 2026. The analyst writes that favorable safety (with no risk of JAK class black box warning) and potential BIC efficacy make ESK-001 a potentially competitive alternative to ava
Whales with a lot of money to spend have taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 77% of the investors opened trades with bullish expectations and 22% with bearish. From the overall spotted trades, 3 are puts, for a total amount of $130,505 and 6, calls, for a total amount of $278,695. Expected Price Movements Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $130.0 to $160.0 for Johnson & Johnson over the last 3 months. Analyzing Volume & Open
Pharma giant Johnson & Johnson (NYSE:JNJ) announced Monday it had asked the Food and Drug Administration (FDA) to approve its nasal spray as a monotherapy for treatment-resistant depression (TRD) in adults. The New Jersey-based company's Spravato, contains esketamine as an active ingredient, which is a nasal spray derivative formulation of a dissociative anesthetic, ketamine. While for years, ketamine has been used as an anesthetic in medical settings, recent clinical trials led to its broader application, most commonly for depression treatment. FDA approved Spravato in 2019 but only in combination with oral antidepressants; it is available through a restricted program requiring monito
Daiwa Capital analyst Narumi Nakagiri downgrades Johnson & Johnson (NYSE:JNJ) from Outperform to Neutral and lowers the price target from $160 to $150.
President Joe Biden‘s decision on Sunday to drop his bid for a second term in the White House was “yet another curveball for equity investors,” according to RBC Capital Markets analyst Lori Calvasina. So far this year, investors have exhibited “the same amount of discomfort in talking about the US election and its stock market/economic implications in our meetings that one might feel by staring at the sun for too long,” Calvasina wrote in a Monday analyst note. How the stock market will react to Biden’s historic decision “remains to be seen,” she adds. “The main thing we've been remembering,” Calvasina says, “is how so many of the US-based investors we've spoken with this year seeme
Monday, Addex Therapeutics (NASDAQ:ADXN) announced its partner Janssen Pharmaceuticals, Inc, a unit of Johnson & Johnson (NYSE:JNJ), has discontinued the development of ADX71149 (JNJ-40411813) in epilepsy. The partnership between the two companies remains ongoing while the full data set from the Phase 2 study of ADX71149 (JNJ-40411813) as an adjunctive epilepsy treatment is analyzed. The decision follows top-line Phase 2 data announced in April, showing that adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam did not achieve statistical significance for the primary endpoint of time for patient
Johnson & Johnson (NYSE:JNJ) faced a legal setback on Friday when a New Jersey judge rejected its bid to disqualify the law firm Beasley Allen from representing plaintiffs who claim the company’s talc products caused their cancer. This decision complicates Johnson & Johnson’s attempt to resolve over 60,000 claims through a $6.48 billion pre-packaged bankruptcy plan, Reuters reports. Judge John Porto of the New Jersey Superior Court ruled that Johnson & Johnson had not provided “any credible basis” for its allegations that Beasley Allen partner Andy Birchfield formed an unethical alliance with a former Johnson & Johnson lawyer. In a related development, U.S. Magistrate Judge Rukhsana
Goldman Sachs analyst Chris Shibutani maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and lowers the price target from $160 to $155.
Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 15th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of th
Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2024 of $1.24 per share on the company's common stock. The dividend is payable on September 10, 2024 to shareholders of record at the close of business on August 27, 2024. The ex-dividend date is August 27, 2024. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely p
2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%* 2024 Second-Quarter Earnings per share (EPS) of $1.93 decreasing by 5.9% due to one-time special charges and adjusted EPS of $2.82 increasing by 10.2%* Significant new product pipeline progress including TREMFYA IBD and subcutaneous filings, RYBREVANT subcutaneous filing, and VARIPULSE admIRE data release Company increases Full-Year 2024 operational sales5 guidance to reflect the acquisition of Shockwave Medical Company updates Full-Year 2024 adjusted operational EPS guidance
NM26 is a Phase 2-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD) The Company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases Johnson & Johnson1 (NYSE:JNJ) announced today that it has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody, in an all-cash transaction of approximately $1.25 billion, as announced on May 28, 2024. NM26, which is ready to enter Phase 2 studies in atopic dermatitis (AD), targets two clini
Acquisition includes two pre-clinical bispecific antibodies targeting proven disease pathways, offering the potential to transform the treatment paradigm for patients living with atopic dermatitis and other immune-mediated diseases Johnson & Johnson (NYSE:JNJ) announced today that it has successfully completed the acquisition of Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash with potential for an additional milestone payment, as announced on May 16, 2024. "We look forward to continuing the development of PX-128 and PX-130 alongside the Proteologix team as they join Johnson & Johnson," said
Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 17th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of th
J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights NM26 is a Phase 2-ready bi-specific antibody from Numab's pipeline of candidates, discovered and engineered using its proprietary MATCH™ technology platform HORGEN, Switzerland, May 28, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (Numab), a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics, announced today that the Company has entered into a definitive agreement whe
SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. "The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams," said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. "Our team is looking forward to continuing our mission as part of Johnson & Johnson and to
The Plan would resolve 99.75% of all pending talc lawsuits against Johnson & Johnson and its affiliates in the United States Johnson & Johnson (NYSE:JNJ) (the "Company") today announced a proposed Plan of Reorganization (the "Plan") by its subsidiary, LLT Management LLC ("LLT"), for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation against it and its affiliates in the United States. "The Plan is the culmination of our consensual resolution strategy that we announced last October," said Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson. "Since then, the Company has worked with counsel
Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 4.2% increase in the quarterly dividend, from $1.19 per share to $1.24 per share, marking the 62nd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $4.96 per share compared to the previous rate of $4.76 per share. The next quarterly dividend is payable on June 4, 2024 to shareholders of record at the close of business on May 21, 2024. The ex-dividend date is May 20, 2024. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, tr
For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin
For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not
For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione
For Immediate Release: August 03, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: In mid-July, the FDA held a stakeholder call to discuss COVID-19 vaccines, including preliminary reports of Guillain-Barré Syndrome following Janssen (Johnson & Johnson) COVID-19 vaccination. Acting FDA Commissioner Janet Woodcock, M.D.
For Immediate Release: July 30, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: Today, the FDA revised the Emergency Use Authorization (EUA) for REGEN-COV (casirivimab and imdevimab, administered together) to add an authorization of REGEN-COV for emergency use as post-exposure prophylaxis (prevention) for COVID-19 in
For Immediate Release: July 13, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: Today, the FDA is announcing revisions to the vaccine recipient and vaccination provider fact sheets for the Johnson & Johnson (Janssen) COVID-19 Vaccine to include information pertaining to an observed increased risk of Guillain-Barré Sy
For Immediate Release: June 11, 2021 Following careful review and deliberation, the U.S. Food and Drug Administration is taking important steps that will allow a critically needed supply of the Janssen (Johnson & Johnson) COVID-19 Vaccine to be made available. The agency is announcing today that it is authorizing for use, under the emergency use authorization (EUA) for the Janssen COVID-19 vaccine, two batches
For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry
For Immediate Release: May 18, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On May 17, the FDA provided summary information about the status of CytoDyn, Inc.’s development program for the monoclonal antibody investigational drug, leronlimab, for the treatment of COVID-19. The data currently available from recent C
For Immediate Release: April 27, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: As part of the FDA’s effort to protect consumers, the agency issued a warning letter to an operator of one website, www.pharmacygeoff.md for marketing unapproved drugs for multiple diseases, including COVID-19. Drugs that have circumven
SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024. Dr. Gottardis is the owner of, and has served as a consultant at, Gottardis Biotech LLC, a biopharmaceuticals and research and development consultancy firm, since February 2023. Dr. Gottardi
NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For
Johnson & Johnson (NYSE:JNJ) announced today that Eugene A. Woods, MBA, MHA, Chief Executive Officer of Advocate Health, has been appointed to its Board of Directors. "Mr. Woods is an exceptional addition to Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "Mr. Woods has an impressive career of leading and transforming healthcare systems while prioritizing the delivery of high-quality, equitable patient care. The Board looks forward to working with him as the Company continues to focus on healthcare innovation and tackling the toughest health challenges." "It is an honor to join the Johnson & Johnson Board of Directors
Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation. "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong internationa
International industry executive Piet Hinoul joins Virtual Incision as chief medical officer, Dmitry Oleynikov transitions to chief surgeon Virtual Incision Corporation, a medical device company developing the world's first miniaturized robotic-assisted surgery (RAS) system, today announced the appointment of global healthcare executive Piet Hinoul, MD, PhD, as chief medical officer (CMO). The company's current CMO Dmitry Oleynikov, MD, FACS will take on the newly established role of chief surgeon, focusing on the research and development of new RAS technology. The expansion of the team strengthens Virtual Incision at a transformative point in its trajectory as it develops new market growt
Johnson & Johnson (NYSE:JNJ) (the Company) today announced the appointment of John Reed, M.D., Ph.D., to the Company's Executive Committee as Executive Vice President of Pharmaceuticals, R&D. Dr. Reed previously served as Executive Vice President, Global Head of Research and Development for Sanofi and brings more than 35 years of biomedical research leadership to the Company. Dr. Reed will join Johnson & Johnson on April 3, 2023, assuming responsibility for the Company's industry-leading portfolio from William Hait, M.D., Ph.D., who has served as interim head of Johnson & Johnson's Pharmaceutical R&D organization since August 2022. Joaquin Duato, Chairman of the Board and Chief Executive
Former President and CEO of CVS Health, Merlo Will Assume Board Leadership Role with the New Consumer Health Company and Support Preparations for the Planned Separation, Expected to Occur in 2023 Johnson & Johnson (NYSE:JNJ) today announced the appointment of Larry Merlo as Non-executive Chair Designate for the future, listed New Consumer Health Company's Board of Directors. Merlo previously served as President and CEO of CVS Health and brings over 30 years of purpose-driven and transformative health leadership to the Board for the planned new company. As announced in November 2021, the planned separation would create two global leaders – the new Johnson & Johnson and the New Consumer Hea
The Company has also appointed Paul Ruh as CFO Designate Mongon and Ruh to Assume New Leadership Roles Upon the Completion of the Planned Separation of the Consumer Health Business Planned Separation Expected to Occur in 2023 NEW BRUNSWICK, N.J., May 11, 2022 /PRNewswire/ -- Johnson & Johnson (the "Company") (NYSE:JNJ) today announced the appointment of Thibaut Mongon as Chief Executive Officer Designate and Paul Ruh as Chief Financial Officer Designate of the future, listed New Consumer Health Company. As announced in November 2021, the planned separation would create two global leaders – the new Johnson & Johnson and the New Consumer Health Company - that are better positioned to delive
Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational platform to identify and develop small molecule therapeutics across a broad range of diseases, announced today the appointment of Victor Lobanov, Ph.D., as Senior Vice President, Head of Computational Sciences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220404005164/en/Victor Lobanov, Ph.D., Ventus Senior Vice President, Head of Computational Sciences (Photo: Business Wire) Dr. Lobanov brings to Ventus more than 25 years of experience in developing and implementing leading-edge computational methods across the d
MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the appointment of Valerie L. Asbury and D. Brent Shafer to the Company's Board of Directors ("Board"), effective January 5, 2022. Ms. Asbury will serve as a member of both the Audit Committee and the Compliance & Reimbursement Committee. Mr. Shafer will serve as a member of the Audit Committee, the Compensation & Organization Committee, and the Nominating & Corporate Governance Committee. Three long-standing directors will